250 related articles for article (PubMed ID: 32601199)
1. Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways.
Zervantonakis IK; Poskus MD; Scott AL; Selfors LM; Lin JR; Dillon DA; Pathania S; Sorger PK; Mills GB; Brugge JS
Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16500-16508. PubMed ID: 32601199
[TBL] [Abstract][Full Text] [Related]
2. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
[TBL] [Abstract][Full Text] [Related]
3. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
[TBL] [Abstract][Full Text] [Related]
4. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
Amin DN; Ruiz-Saenz A; Gulizia N; Moasser MM
Oncotarget; 2015 Dec; 6(38):41123-33. PubMed ID: 26516700
[TBL] [Abstract][Full Text] [Related]
5. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
6. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
Gayle SS; Arnold SL; O'Regan RM; Nahta R
Anticancer Agents Med Chem; 2012 Feb; 12(2):151-62. PubMed ID: 22043997
[TBL] [Abstract][Full Text] [Related]
8. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
9. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
11. Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
Korkola JE; Collisson EA; Heiser M; Oates C; Bayani N; Itani S; Esch A; Thompson W; Griffith OL; Wang NJ; Kuo WL; Cooper B; Billig J; Ziyad S; Hung JL; Jakkula L; Feiler H; Lu Y; Mills GB; Spellman PT; Tomlin C; Mukherjee S; Gray JW
PLoS One; 2015; 10(7):e0133219. PubMed ID: 26181325
[TBL] [Abstract][Full Text] [Related]
12. HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment.
Li J; Xiao Q; Bao Y; Wang W; Goh J; Wang P; Yu Q
Cell Cycle; 2019 Jul; 18(13):1513-1522. PubMed ID: 31135266
[TBL] [Abstract][Full Text] [Related]
13. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.
Brady SW; Zhang J; Tsai MH; Yu D
Cancer Biol Ther; 2015; 16(3):402-11. PubMed ID: 25692408
[TBL] [Abstract][Full Text] [Related]
14. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
15. CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
Li H; Wang J; Yi Z; Li C; Wang H; Zhang J; Wang T; Nan P; Lin F; Xu D; Qian H; Ma F
Eur J Cancer; 2021 Mar; 145():92-108. PubMed ID: 33429148
[TBL] [Abstract][Full Text] [Related]
16. Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates.
Kaczyńska A; Świerczyńska J; Herman-Antosiewicz A
Nutr Cancer; 2015; 67(6):976-86. PubMed ID: 26134366
[TBL] [Abstract][Full Text] [Related]
17. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
Garay JP; Smith R; Devlin K; Hollern DP; Liby T; Liu M; Boddapati S; Watson SS; Esch A; Zheng T; Thompson W; Babcock D; Kwon S; Chin K; Heiser L; Gray JW; Korkola JE
Breast Cancer Res; 2021 Aug; 23(1):81. PubMed ID: 34344439
[TBL] [Abstract][Full Text] [Related]
19. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
20. Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.
Sato Y; Yashiro M; Takakura N
Cancer Sci; 2013 Dec; 104(12):1618-25. PubMed ID: 24112719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
